Oxytocin attenuates feelings of hostility depending on emotional context and individuals' characteristics

Tetsu Hirosawa¹, Mitsuru Kikuchi¹,², Haruhiro Higashida², Eiichi Okumura⁴, Sanae Ueno¹, Kiyomi Shitamichi¹, Yuko Yoshimura¹, Toshio Munseue¹,², Tsunehisa Tsubokawa¹, Yasuhiro Haruta⁴, Hideo Nakatani¹, Takanori Hashimoto¹ & Yoshio Minabe¹,²

¹Department of Psychiatry and Neurobiology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan, ²Research Center for Child Mental Development, Kanazawa University, Kanazawa, Japan, ³Department of Anaesthesiology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan, ⁴Department of MEG, Yokogawa Electric Corporation, Tokyo, Japan.

In humans, oxytocin (OT) enhances prosocial behaviour. However, it is still unclear how the prosocial effects of OT are modulated by emotional features and/or individuals' characteristics. In a placebo-controlled design, we tested 20 healthy male volunteers to investigate these behavioural and neurophysiological modulations using magnetoencephalography. As an index of the individuals' characteristics, we used the empathy quotient (EQ), the autism spectrum quotient (AQ), and the systemising quotient (SQ). Only during the perception of another person's angry face was a higher SQ a significant predictor of OT-induced prosocial change, both in the behavioural and neurophysiological indicators. In addition, a lower EQ was only a significant predictor of OT-induced prosocial changes in the neurophysiological indicators during the perception of angry faces. Both on the behavioural and the neurophysiological level, the effects of OT were specific for anger and correlated with a higher SQ.

Humans are social creatures, and prosocial behaviour is crucial for the interaction of individuals with their environment. Oxytocin (OT) has attracted attention regarding the neurological basis of prosocial behaviours that facilitate interpersonal relationships (e.g., perceptions of trustworthiness, attractiveness and approachability). OT is a hormone that is primarily synthesised in the central nervous system and plays an important role in the regulation of the development of prosocial behaviour and in various reproductive effects, such as parturition and lactation¹. In animal models, OT is essential for social interactions²,³, and these animal studies have led to a number of human studies to investigate the mechanisms of this prosocial effect⁴–¹². Intriguingly, recent human studies have shown that the administration of OT facilitates temporary attachment between strangers, increasing trust, reciprocity, generosity¹³–¹⁵, and positively modulate sociality¹,¹⁰–¹²,¹⁷,¹⁸. In addition, the amygdala is rich in OT receptors¹⁹,²⁰, and OT acts as an anxiolytic by reducing activity in the amygdala²¹. This anxiolytic-like effect may contribute to human prosocial behaviour by reducing anxiety in personal relations¹.

Although the above-mentioned studies suggest the potential of OT to facilitate sociality, a minority of published studies indicated the opposite result, i.e., antisocial effects, such as increased feelings of envy²², mistrust²³, attachment insecurity²⁴, or outgroup derogation²⁵. Thus, a recent review suggested that the positive effects of OT on sociality may depend on context or individual factors²⁶. With regard to OT’s effect on prosociality, no previous study has demonstrated either how contextual and individual differences factors modulate the effects of OT on neural responses to social stimuli or how the neural effects of OT parallel its nuanced prosocial behavioural effects. This is the first study that addresses the individual-dependent effects of OT on prosocial behaviour.

There is accumulating evidence that OT has critical implications for autism spectrum disorder (ASD), in which deficits in social behaviour are common²⁷. For example, children with autism have lower plasma OT levels compared with age-matched controls²⁸, and polymorphisms of multiple OT-related genes are associated with ASD²⁹. Thus, ASD is a good candidate for treatment with OT, and several symptoms of ASD can be ameliorated by OT administration³⁰,³¹. Considering the association between OT and ASD, we speculated that individuals with autistic-like traits would benefit from OT. Traits of ASD have been characterised using the following three

SUBJECT AREAS:
NEURODEVELOPMENTAL DISORDERS
BEHAVIOUR
MEDICINAL CHEMISTRY
NEUROIMAGING

Received
18 January 2012
Accepted
30 March 2012
Published
26 April 2012

Correspondence and requests for materials should be addressed to M.K. (mitsuru@zc4.so-net.ne.jp)
dimensions: empathy quotient (EQ), autism spectrum quotient (AQ), and systemising quotient (SQ). These three dimensions can be used to assess milder variants of autistic-like traits (i.e., low EQ, high AQ and high SQ) in typically developing individuals. Empathy is an essential part of normal social functioning that allows us to understand the intentions of others, predict their behaviour, and experience an emotion triggered by their emotion. EQ is a self-report questionnaire for use with adults of normal intelligence that focuses purely on this domain. Systemising is the drive to analyse the variables in a system and derive the underlying rules that govern the behaviour of a system. SQ is a self-report questionnaire for use with adults of normal intelligence that focuses purely on this domain across the range of different system classes.

Magnetoencephalography (MEG) is a neurophysiological technique that records the magnetic sources generated from simultaneous firing of groups of pyramidal cells. Unlike indirect measures such as functional magnetic resonance imaging (fMRI), which records aspects of blood flow, MEG directly records neuronal activity and thus records real-time neural activity. In addition, MEG provides not only excellent temporal resolution (on the order of milliseconds) but also good spatial resolution with appropriate source modelling methods. Recent advantages in source analysis methods based on the adaptive beamformer approach enable the estimation of source current power changes in an arbitrarily chosen voxel (e.g., amygdala) within the whole brain at high resolution. Using such methods, recent studies demonstrated that gamma band (30–50 Hz) event-related synchronisation (ERS), which is defined as a localised increase in oscillatory power, was predominant in the amygdala compared to other parts of the brain, especially during the perception of negative facial emotions (e.g., angry or fearful). This gamma ERS in the amygdala is a candidate for the neurophysiological underpinning of brain responses to emotionally negative stimuli and is associated with modulation of the brain response in the amygdala. Thus, we examined whether, even in healthy individuals, higher SQ or AQ scores and/or lower EQ scores (i.e., personality traits often found in ASD) would be significant predictors of an OT-induced reduction in the hostility detection ratio (i.e., the percentage of hostile responses among all responses) during the perception of others’ angry and/or ambiguous facial expressions and in the OT-induced attenuation of gamma ERS in the amygdala. From the perspective of functional lateralisation in the amygdala, the involvement of both the left and the right amygdala in response to emotional faces has been reported using fMRI; however, the reason why individual studies report greater lateralisation for one side or the other remains unclear. Then, in the present study, we analysed gamma ERS in the amygdala in each hemisphere. From the perspective of diversity in facial expression, as shown in Figure 1B, we employed ambiguous facial expression in addition to the conventional facial expressions (anger, happiness and neutral) because one recent study suggested that increased amygdala reactivity is associated with behavioural responses to ambiguous facial expression. In this study, we defined ambiguous facial expression as follows: it is difficult to infer the emotions although some facial expressions are present.

**Results**

As shown in Figure 2, the experimental sessions were conducted in a single-blind, placebo-controlled, within-subject, crossover design, with an interval of at least two weeks. The order of the two conditions (OT or placebo) was counterbalanced across subjects by random selection. We excluded one subject from the neurophysiological analysis because of unrecoverable magnetic noise caused by a dental bridge. Thus, in the statistics for the physiological data, subjects consisted of 19 men (10 started with the OT condition, and 9 started with the placebo condition), whereas all subjects were included in the statistics for behavioural data (10 started with the OT condition, and 10 started with the placebo condition).
Correlation between oxytocin-induced behavioural changes and autistic traits (n = 20). In the present study, our main concern was to evaluate how prosocial effects are constrained by individuals' personality in each emotional condition. We performed multiple linear regressions to predict the placebo-subtracted changes after OT treatment in the hostility detection ratio or reaction time (i.e., dependent variables) using AQ, EQ, and SQ scores as predictors (i.e., three independent variables) for each emotional condition. Statistical significance was defined as P<0.05.

There were no significant correlations among independent variables (correlation coefficients r = -0.190, -0.085, and 0.207 when comparing AQ and EQ, AQ and SQ, and EQ and SQ scores, respectively).

For the hostility detection ratio, the multiple regression model revealed that a high SQ score was a significant predictor of the placebo-subtracted changes in the hostility detection ratio for facial emotions after OT treatment only in the anger condition (n = 20, β = −0.334, P = 0.032), whereas AQ (n = 20, β = −0.368, P > 0.05) and EQ scores (n = 20, β = −0.306, P = 0.05) did not reach statistical significance (Table 1). In other emotional conditions (i.e., happiness, ambiguous, or neutral), no independent factors were significant predictors of the placebo-subtracted behavioural changes after OT treatment (P > 0.05) (Table 1).

For reaction time, no independent factors (i.e., AQ, EQ and SQ) were significant predictors of the placebo-subtracted changes in reaction time after OT treatment for any facial emotion (P > 0.05).

We performed multiple linear regressions to predict the placebo-subtracted changes after OT treatment in neurophysiological variables (i.e., dependent variables) using AQ, EQ, and SQ scores as predictors (i.e., three independent variables) for each emotional condition. Statistical significance was defined as P = 0.025 for neurophysiological variables (in the left and right region of interests (ROIs)).

For the right amygdala, the multiple regression model revealed that lower EQ (n = 19, β = 0.729, P < 0.001) and higher SQ (n = 19, β = −0.550, P = 0.002) scores were significant predictors of placebo-subtracted neurophysiological changes (i.e., decreased gamma ERS in the right amygdala) for facial emotion after OT treatment only in the anger condition, whereas the AQ score (n = 19, β = −0.136, P > 0.025) did not reach statistical significance (Table 2). In other emotional conditions (i.e., happiness, ambiguous, or neutral), no independent factors were significant predictors of placebo-subtracted neurophysiological changes after OT treatment (P > 0.025) (Table 2).

For the left amygdala under all emotional conditions (i.e., happiness, anger, ambiguous, or neutral), no independent factors were significant predictors of the placebo-subtracted neurophysiological changes after OT treatment (P > 0.025) (Table 3).

A two-way ANCOVA (emotion x drug) for behavioural changes after treatment (n = 20). For behavioural changes (pre-treatment

---

**Table 1** | Standardised regression coefficient β and t values for the multiple regression models with the placebo-subtracted behavioural changes for each facial emotion after OT treatment as the dependent variable. AQ, EQ, and SQ scores were utilised as the independent variables.

|               | AQ  | EQ  | SQ  | n   | R²  |
|---------------|-----|-----|-----|-----|-----|
| Happiness     | β = -0.167 | 0.246 | 0.002 | 20   | 0.104 |
|               | t = -0.692 | 1.001 | 0.008 |      |      |
| Anger         | β = -0.368 | -0.306 | -0.457 | 20   | 0.425 *|
|               | t = -1.904 | -1.553 | -2.356 |      |      |
| Ambiguity     | β = 0.001  | -0.029 | -0.334 | 20   | 0.116 |
|               | t = 0.003  | -0.119 | -1.388 |      |      |
| Neutrality    | β = -0.245 | 0.069 | -0.300 | 20   | 0.140 |
|               | t = -1.038 | 0.285 | -1.264 |      |      |

n: number of subjects, * P < 0.05

OT, oxytocin; AQ, autism quotient; EQ, empathy quotient; SQ, systemising quotient.

---

**Table 2** | Standardised regression coefficient β and t values for the multiple regression models with the placebo-subtracted gamma ERS changes in the right hemisphere for each facial emotion after OT treatment as the dependent variable. AQ, EQ, and SQ scores were utilised as the independent variables.

|               | AQ  | EQ  | SQ  | n   | R²  |
|---------------|-----|-----|-----|-----|-----|
| Happiness     | β = -0.409 | 0.087 | 0.284 | 19   | 0.274 |
|               | t = -1.831 | 0.381 | 1.101 |      |      |
| Anger         | β = -0.131 | 0.045 | -0.417 | 19   | 0.178 |
|               | t = -0.553 | 0.187 | -1.738 |      |      |
| Ambiguity     | β = 0.036  | -0.090 | -0.381 | 19   | 0.172 |
|               | t = 0.150  | -0.368 | -1.583 |      |      |
| Neutrality    | β = 0.198  | 0.117 | 0.259 | 19   | 0.137 |
|               | t = 0.811  | 0.715 | 1.056 |      |      |

n: number of subjects. These results did not reach significance (P > 0.025).

ERS, event-related synchronisation; OT, oxytocin; AQ, autism quotient; EQ, empathy quotient; SQ, systemising quotient.
values were subtracted from post-treatment values) in the hostility detection ratio or reaction time, a two-way ANCOVA was performed (emotion\times drug) using the AQ, EQ and SQ scores as covariates. All factors were within subjects for emotion effect (happiness vs. anger vs. ambiguity vs. neutral) and drug effect (OT vs. placebo). Statistical significance was defined as \( P<0.05 \).

For behavioural changes in the hostility detection ratio after treatment, there were no significant emotion effects (df=3, F=1.04, \( P>0.05 \)) or drug effects (df=1, F=1.28, \( P>0.05 \)), and there were no significant interactions between these two factors (df=3, F=1.00, \( P>0.05 \)). There were no significant interactions between these two factors and covariates (\( P>0.05 \)).

For behavioural changes in reaction time after treatment, there were no significant emotion effects (df=3, F=1.69, \( P>0.05 \)) or drug effects (df=1, F=0.03, \( P>0.05 \)), and there were no significant interactions between these two factors (df=3, F=0.37, \( P>0.05 \)). Among these factors and covariates, only one significant interaction was found between an emotion effect and the AQ score (df=3, F=4.79, \( P=0.017 \)).

A three-way ANCOVA (emotion\times hemisphere\times drug) for changes in gamma ERS (n=19). For changes in neurophysiological variables after treatment (i.e., gamma ERS in the amygdala), a three-way ANCOVA was performed (emotion\times hemisphere\times drug) using the AQ, EQ and SQ scores as covariates. All factors were within subjects for an emotion effect (happiness vs. anger vs. ambiguity vs. neutral), hemisphere effect (left vs. right), and drug effect (OT vs. placebo). Statistical significance was defined as \( P<0.05 \). A three-way ANCOVA revealed no significant emotion effect (df=3, F=1.39, \( P>0.05 \)), hemisphere effect (df=1, F=0.81, \( P>0.05 \)), or drug effect (df=1, F=0.02, \( P>0.05 \)). There were no significant interactions among factors, i.e., emotion \times hemisphere (df=3, F=1.40, \( P>0.05 \)), hemisphere \times drug (df=1, F=0.21, \( P>0.05 \)), emotion \times drug (df=3, F=0.55, \( P>0.05 \)), or emotion \times hemisphere \times drug (df=3, F=1.23, \( P>0.05 \)). Among these factors and covariates, only one significant interaction was found between emotion, drug and SQ score (df=3, F=4.81, \( P=0.018 \)).

Validation of the facial emotional pictures. To validate the facial emotional pictures used in our visual task, a group of another healthy volunteers (n=15) was asked to evaluate whether the facial emotions indicated happiness, neutrality, or anger according to the emotion expressed by the photographic subject. As shown in Figure 3, all 37 pictures categorised as showing “happy”, “angry”, and “neutral” facial emotion were identified correctly by an average of more than 70% of all healthy volunteers. On the other hand, 37 pictures categorised as “ambiguous” were not recognised as happy, angry, or neutral by an average of more than 40% of the healthy volunteers.

A two-way ANOVA (emotion\times hemisphere) for gamma ERS in the amygdala (n=19). To confirm the neurophysiological (i.e., gamma ERS) responses in the amygdala during the perception of various facial emotions, a two-way ANOVA was performed without any covariates (i.e., AQ, EQ and SQ scores) for the conditions before placebo administration. Two factors were analysed within subjects for the emotion effect (happiness vs. anger vs. ambiguity vs. neutral) and the hemispheric effect (left vs. right). Statistical significance was defined as \( P<0.05 \). A two-way ANOVA revealed a significant emotion effect (df=3, F=2.938, \( P=0.041 \)) but no significant hemispheric effect (df=1, F=0.814, \( P>0.05 \)). There was no significant interaction between these two factors (df=3, F=0.922, \( P>0.05 \)). Post-hoc analyses showed that the gamma ERS in the amygdala was larger for the anger condition than for the happiness condition (\( P=0.005 \)). Error bars indicate 1 standard error.

Figure 4 | A, ROI analyses for gamma ERS before placebo administration. A two-way ANOVA revealed a significant emotion effect (df=3, F=2.938, \( P=0.041 \)) but no significant hemispheric effect (df=1, F=0.814, \( P>0.05 \)). There was no significant interaction between these two factors (df=3, F=0.922, \( P>0.05 \)). Post-hoc analyses showed that gamma ERS in the amygdala was larger for the anger condition than for the happiness condition (\( P=0.005 \)). Error bars indicate 1 standard error.

Discussion

We examined how the effects of OT on human behaviour and underlying brain activity are constrained by the features of emotional
situations and/or individual characteristics. As we hypothesised, higher SQ scores and lower EQ scores were significant predictors of OT-induced attenuation of gamma band ERS in the right amygdala during angry facial perception (Figure 5B). In addition, a higher SQ score was a significant predictor of the OT-induced decrease in the hostility detection ratio during angry facial cognition (Figure 5A). Unexpectedly, during ambiguous facial cognition, no individual factors (i.e., EQ, AQ and SQ) were significant predictors of the behavioural changes after OT treatment both in behavioural and physiological results. These findings suggested that, in case of individuals with higher SQ and obvious negative emotional cognition, the OT tends to suppress brain activities in the right amygdala and decrease the emotional discomfort that can be associated with hostility detection.

As shown in the results of a two-way ANCOVA (emotion × drug) for the behavioural data, we did not find any significant main effect of drug (i.e., OT or placebo) or drug-related interactions. Thus, we found no significant prosocial effect of OT, whereas two previous behavioural studies indicated that it had prosocial effects in facial cognition. These differences may be due to dissimilarities between the participants within the different samples. For example, one previous study recruited subjects from universities, whereas we recruited subjects from the general population. Most of the subjects in the present study were workers in non-technical fields which is different from mathematically intensive fields (mathematics, engineering, computer science and physical sciences) in which populations could have deviated traits (e.g., high systemising and/or low empathising traits). Furthermore, our results were consistent with the recent suggestion that the effect of OT is not prosocial in everyone.

Recent fMRI studies in male subjects demonstrated the suppressive effects of OT on the amygdala response to negative facial emotions, whereas our MEG study, as a whole, did not demonstrate a significant effect of OT in the amygdala. These differences could be explained by different methodologies (i.e., fMRI vs. MEG). There are essential differences in the time scale and meaning to which these two imaging modalities are applied. MEG records neuronal activity directly; thus, in the present study, we could record real-time neural activity with 200-ms time windows starting 100 ms after stimulus onset, whereas fMRI measures the brain haemodynamic response that occurs a few seconds after the start of the stimulus and is an indirect measurement of neuronal activity. In addition, these differences may also be due to dissimilarities between participants of the different samples, as mentioned above. In terms of the diversified effect of OT administration on amygdala and the individuals’ characteristics, one suggestive study demonstrated that female subjects showed enhanced haemodynamic response in the amygdala during the perception of negative emotional face after OT administration. This result is at odds with the previously reported suppressive effects on amygdala found in men. This diversified effect of OT on amygdala in previous studies may be explained by the opposing empathising and systemising trends observed between men and women (i.e., men tend to show high systemising and/or low empathising traits compared with women).

Significantly higher SQ and lower EQ scores have been reported in ASD subjects with normal intelligence. In addition, recent studies reported that several symptoms of ASD can be ameliorated by OT administration. These facts are consistent with the hypothesis that healthy individual with high SQ and low EQ (i.e., ASD traits) may also be beneficial responders to OT administration (i.e., that OT will suppress the amygdala).

To confirm the neurophysiological (i.e., gamma ERS) responses in the amygdala during the perception of various facial emotions, a two-way ANOVA was performed without any covariates (i.e., AQ, EQ and SQ scores) before placebo administration. In the present study, we confirmed the emotion-dependent gamma band (30–50 Hz) ERS in the amygdala, which was predominant during the perception of negative facial emotion (e.g., anger) (Figure 4) and largely replicated the results of previous MEG studies. A number of neurophysiological studies have suggested that gamma band synchronisation plays a crucial role in integrating distributed neural processes into highly ordered cognitive functions. With regard to emotional processing, gamma band oscillation has been associated with negative emotional face processing within the amygdala. Therefore, we hypothesised that the observed higher gamma ERS in the present study indicated the brain emotional responses to the negative facial emotions.

There were some limitations in the present study. First, the sample of 20 participants was rather small and consisted only of male subjects. It will be important to replicate the findings in a larger sample that includes both sexes with a greater age range. Second, the phenomenon that decreases of the hostility detection ratio after OT...
administration could be explained by either “deterioration of cognitive performance” or by “prosocial effect.” Further study with fine evaluation of OT effect on facial cognition is necessary to distinguish between these explanations. Third, relative to previously published studies in males without ASD, our participants had relatively lower SQ and AQ scores (e.g., 114 healthy males in previous study showed 3.03 + 1.42 on the SQ and 38.8 + 12.1 on the AQ; 76 healthy males in a previous study showed a mean scores of 17.8 ± 6.8 on the AQ). We cannot exclude the possibility that these differences in the characteristics of participant have an impact on our results. Fourth, because substance administration was executed in a single-blind manner (i.e., the experimenter knew the composition of the groups but the participants did not), this strategy does not allow us to firmly exclude the possibility that the experimenter involuntarily influenced the findings. This possibility is unlikely because (a) the verbal contact with the experimenter was limited (all instructions during the task were given by the computer), and (b) instructions were fully standardised.

This is the first study indicating how empathising and systemising traits modulate the effects of OT in the amygdala during the perception of social stimuli and how the neural effects of OT parallel its nuanced prosocial behavioural effects. We characterised the emotion- (i.e., anger) and individual- (i.e., low EQ and/or high SQ score) dependent nature of the prosocial effects of OT, which may enable refined theorising on the social effects of OT in humans. Viewing the effects of OT in this way sheds new light on existing and emerging experimental data and has crucial implications for more individualised use of OT as a therapeutic agent for ASD and/or other psychiatric disorders.

Methods
Participants. Twenty right-handed adult men participated in the experiment. The participants had a mean age of 31.4 years (20–46). The mean scores (± SD) of the AQ, EQ, and SQ were 13.9 ± 3.7, 37.3 ± 9.8 and 21.6 ± 12.7, respectively. All subjects were native Japanese and had no previous or existing psychiatric, neurological, or medical illnesses. Subjects were screened with a structured clinical interview for DSM-IV (SCID-I/NP) to exclude a personal history of psychiatric illness. Subjects were not on any medication at least 6 weeks prior to testing and reported a normal sleep/wake cycle. Written informed consent was obtained prior to enrolment in the study. The Ethics Committee of Kanazawa University Hospital approved the methods and procedures, all of which were performed in accordance with the Declaration of Helsinki.

Experimental design. The experimental sessions were conducted in a single-blind, placebo-controlled, within-subject, crossover design, with an interval of at least two weeks. The order of the two conditions (OT or placebo) was counterbalanced across subjects by random selection. Thereafter, participants completed the AQ, EQ, and SQ. Participants were randomly assigned to receive either a single intranasal dose of either 2 IU OT (Syntocinon; Novartis, Basel, Switzerland) or the placebo control during the first experiment. Following published pharmacokinetics, subjects were randomized to receive OT or placebo with a resolution of 512×512 points in a field of view of 261×261 mm. After reconstructing the three-dimensional MRI, the best-fit sphere was determined for each participant’s head.

MEG recordings. Magnetic fields were measured in a whole-head-type system for adults at the Laboratory of Yokogawa Electric Corporation in Japan. This system (MEGvision PQA160C, Yokogawa Electric Corporation, Yokogawa, Japan) consisted of 160 channels. Sensors were configured as first-order coaxial gradiometers with a baseline of 5 mm; each coil of the gradiometers measured 15.5 mm in diameter. Magnetic fields were sampled at 1000 Hz per channel (band pass 0.16–200 Hz). Using a Signa Excite HD 1.5-T system (GE Yokogawa), all subjects underwent T1-weighted magnetic resonance imaging (MRI) study with spherical lipid markers placed at the MEG fiduciary points to enable us to superpose the MEG coordinate system with the MRI data. The MRI consisted of 160 1.2-mm sections. The 3D spherical shape with a resolution of 512×512 points provided a visual field of 261×261 mm. After reconstructing the three-dimensional MRI, the best-fit sphere was determined for each participant’s head.

MEG data analysis for the gamma band ERS in the amygdala. On the basis of previous studies, the magnetic field data of each subject and each emotional face condition were refined into one frequency band of interest, that is, gamma band oscillation (30–50 Hz). The current density for each voxel was then calculated by adaptive spatial filtering using a single spherical volume conductor-model based on the individual MR images. Power changes in the current density between the active and baseline periods for each voxel were calculated with a 5-mm spherical grid. The active period was defined as the time between 200 and 0 ms before stimulus onset, and the active periods of interest were defined as 200 ms windows starting 100 ms after stimulus onset. Adaptive spatial filtering is a spatial filtering approach to source reconstruction that can estimate neuromagnetic activities with high spatial resolution by forming a linear combination of sensors that can suppress the signals from extraneous noise or other brain areas without attenuating the power from the target voxel. The approach is optimised for time frequency source reconstructions from MEG/EEG data. Details of the adaptive spatial filtering in this study are presented in the supplemental information. The functional images were normalised relative to template brain images created by the Montreal Neurological Institute (MNI) template (in SPM8; Welcome Department of Cognitive Neurology, London, UK; http://www.fil.ion.ucl.ac.uk/spm/software/spm8/). Region-of-interest (ROI) analysis was performed for amygdala gamma band ERS. Data extraction for ROI analyses was performed using MarsBar provided with a sophisticated template for ROIs on SPM-normalised images [MARSelle Boîte À Région d’Intérêt]. The details of this ROI procedure have been reported previously.

---

1. Donaldson, Z. R. & Young, L. J. Oxytocin, vasopressin, and the neurogenetics of sociality. Science 322, 900–904 (2008).
2. Jin, D. et al. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature 446, 41–45 (2007).
3. Higashida, H. et al. Oxytocin signal and social behaviour: comparison among adult and infant oxytocin, oxytocin receptor and CD38 gene knockout mice. J Neuroendocrinol 22, 373–379 (2010).
4. Muneshe, T. et al. Two genetic variants of CD38 in subjects with autism spectrum disorder and controls. Neurosci Res 67, 181–191 (2010).
5. Wunderer, E. M. et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 61, 498–503 (2007).
6. Evans, S., Shergill, S. S. & Averbeck, B. B. Oxytocin decreases aversion to angry faces in an associative learning task. Neuropsychopharmacology 35, 2502–2509 (2010).
7. Simeon, D. et al. Oxytocin administration attenuates stress reactivity in borderline personality disorder: A pilot study. Psychoneuroendocrinology (2011).
8. Guastella, A. J., Mitchell, P. B. & Dadds, M. R. Oxytocin increases gaze to the eye region of human faces. Biol Psychiatry 63, 3–5 (2008).
9. Domes, G. et al. Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology 35, 83–93 (2010).
10. Gamer, M., Zanussi, B. & Bache, C. Different amygdala subregions mediate valence-related and attentional effects of oxytocin in humans. Proc Natl Acad Sci USA 107, 9400–9405 (2010).
11. Kirsch, P. et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 25, 11489–11493 (2005).
12. Petrovic, P., Kalisch, R., Singer, T. & Dolan, R. J. Oxytocin attenuates affective responses to intranasal oxytocin in women. Proc Natl Acad Sci USA 107, 9400–9405 (2010).
13. Barraza, J. A. & Zak, P. J. Empathy toward strangers triggers oxytocin release and subsequent generosity. Ann N Y Acad Sci 1167, 182–189 (2009).
14. Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U. & Fehr, E. Oxytocin systems increase trust in humans. Nature 435, 673–676 (2005).
15. Zak, P. J., Kurzban, R. & Matzner, W. T. The neurobiology of trust. Ann N Y Acad Sci 1032, 224–227 (2004).
16. Theodoridou, A., Rowe, A. C., Penton-Voak, I. S. & Rogers, P. J. Oxytocin and social perception: oxytocin increases perceived facial trustworthiness and attractiveness. Horm Behav 56, 128–132 (2009).
24. Bartz, J. A. et al. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. *Biol Psychiatry* 62, 1187–1190 (2007).

25. De Dreu, C. K., Greer, L. L., Van Kleef, G. A., Halvai, S. & Handgraaf, M. J. Oxytocin promotes human ethnocentrism. *Proc Natl Acad Sci U S A* 108, 1262–1266 (2011).

26. Bartz, J. A., Zaki, J., Bolger, N. & Ochsner, K. N. Social effects of oxytocin in humans: context and person matter. *Trends Cogn Sci* 15, 301–309 (2011).

27. Carter, C. S., Boone, E. M., Pournajafi-Nazarloo, H. & Bales, K. L. Consequences of early experiences and exposure to oxytocin and vasopressin are sexually dimorphic. *Dev Neurosci* 31, 332–341 (2009).

28. Modahl, C. et al. Plasma oxytocin levels in autistic children. *Biol Psychiatry* 43, 270–277 (1998).

29. Baron-Cohen, S. & Wheelwright, S. The empathy quotient: an investigation of autistic and Asperger's disorders. *Autism Res* 7, 163–175 (2004).

30. Baron-Cohen, S., Wheelwright, S., Skinner, L., Martin, J. & Clubley, E. The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. *J Autism Dev Disord* 31, 322–336 (2001).

31. Baron-Cohen, S., Richler, J., Biro, M., Gururangan, N. & Wheelwright, S. The systemizing quotient: an investigation of adults with Asperger syndrome or high-functioning autism, and normal sex differences. *Philos Trans R Soc Lond B Biol Sci* 358, 361–374 (2003).

32. Baron-Cohen, S. & Wheelwright, S. The empathy quotient: an investigation of adults with Asperger syndrome or high-functioning autism, and normal sex differences. *J Autism Dev Disord* 34, 163–175 (2004).

33. Dawson, G. et al. Defining the broader phenotype of autism: genetic, brain, and behavioral perspectives. *Dev Psychopathol* 14, 581–611 (2002).

34. Hohmann, E. et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. *Neuropsychopharmacology* 28, 193–198 (2003).

35. Vrba, J. & Robinson, S. E. Signal processing in magnetoencephalography. *Neuroimage* 308, 729–734 (2008).

36. Valla, J. M. et al. Five-dimensional neuroimaging: localization of the time-frequency dynamics of cortical activity. *Neuroimage* 40, 1686–1700 (2008).

37. Nakatani, H., Higashida, H., Yasuhiro, T., Tsubokawa, Y., Haruta, H. & Minabe, Y. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage* 15, 273–289 (2002).

**Acknowledgments**

We would like to thank Susumu Matsukura (Yokogawa Electric Corporation) for technical support. This study was supported by the Hokuriku Innovation Cluster for Health Science (MEXT Program for Fostering Regional Innovation).

**Author contributions**

Author Tetsu Hirosawa and Mitsuru Kikuchi designed the study and wrote the protocol. Author Haruhiro Higashida, Yuko Yoshimura, Toshio Munesue, Tsunehisa Tsubokawa, Yasuhiro Haruta, Hideo Nakatani, Takanori Hashimoto and Yoshio Minabe managed the study and data. Authors Tetsu Hirosawa, Mitsuru Kikuchi, Haruhiro Higashida, Yuko Yoshimura, Toshio Munesue, Tsunehisa Tsubokawa, Yasuhiro Haruta, Hideo Nakatani, Takanori Hashimoto and Yoshio Minabe analyzed the data and interpreted the results. Authors Tetsu Hirosawa, Mitsuru Kikuchi, Haruhiro Higashida, Yuko Yoshimura, Toshio Munesue, Tsunehisa Tsubokawa, Yasuhiro Haruta, Hideo Nakatani, Takanori Hashimoto and Yoshio Minabe drafted the manuscript. All authors contributed to and have approved the final manuscript.

**Additional information**

**Supplementary information** accompanies this paper at http://www.nature.com/scientificreports

**Competing financial interests:** The authors declare no competing financial interests.

**License:** This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

**How to cite this article:** Hirosawa, T. et al. Oxytocin attenuates feelings of hostility depending on emotional context and individuals' characteristics. Sci. Rep. 2, 384; DOI:10.1038/srep00384 (2012).